Bellevue Group AG Decreases Stock Holdings in TransMedics Group, Inc. $TMDX

Bellevue Group AG lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 24.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 130,517 shares of the company’s stock after selling 43,193 shares during the quarter. Bellevue Group AG’s holdings in TransMedics Group were worth $17,491,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in TMDX. Amalgamated Bank lifted its holdings in shares of TransMedics Group by 0.8% during the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after buying an additional 80 shares during the period. Canada Pension Plan Investment Board increased its position in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the last quarter. Smartleaf Asset Management LLC increased its position in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in TransMedics Group by 4.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock valued at $455,000 after acquiring an additional 142 shares during the period. Finally, Franklin Resources Inc. boosted its position in TransMedics Group by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,842 shares of the company’s stock worth $1,989,000 after purchasing an additional 148 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 0.7%

Shares of TMDX stock opened at $126.79 on Friday. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $156.00. The company’s fifty day moving average price is $126.72 and its 200-day moving average price is $123.13. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of 51.33 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.TransMedics Group’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.12 EPS. Sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at $1,682,257.76. This represents a 29.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director directly owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 13,062 shares of company stock worth $1,797,634. Company insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research reports. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research report on Thursday, September 4th. They set a “hold” rating and a $115.00 price target for the company. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Piper Sandler decreased their price target on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a research report on Thursday, October 30th. Finally, Needham & Company LLC boosted their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $136.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.